Covid-19 roundup: Sci­en­tists in­ves­ti­gate po­ten­tial safe­ty changes to J&J and As­traZeneca vac­cines; WTO lists crit­i­cal in­puts for vac­cine man­u­fac­tur­ing

Sci­en­tists from J&J, As­traZeneca and the Uni­ver­si­ty of Ox­ford are in­ves­ti­gat­ing po­ten­tial mod­i­fi­ca­tions to their Covid-19 vac­cines, to see if it’s pos­si­ble to re­duce or elim­i­nate the risk of blood clots as­so­ci­at­ed with both jabs.

The blood clots are rare, but po­ten­tial­ly fa­tal, as the J&J vac­cine has seen .3 in­stances of clot­ting per 100,000 dos­es ad­min­is­tered, ac­cord­ing to The Wall Street Jour­nal. As­traZeneca has seen be­tween one and two cas­es per 100,000 dos­es. As­traZeneca’s jab has yet to be grant­ed US ap­proval, while the use of J&J’s was briefly halt­ed in April.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER